PRF Sets Dec 21 AGM: 5-to-1 Reverse Split, Share Increase, CEO Pay Votes
PRFX sits 22% above its 52-week low of $0.641.
Summary
PRF's December 21 AGM asks shareholders to approve a 5-to-1 reverse split to cure its Nasdaq delisting notice, double authorized shares to 24,000,000, and sign off on Interim CEO Efi Cohen-Arazi's US$132,000 fee and 100,000 options.
Key Events · Corporate Governance and Compliance · PRFX
-
5-to-1 Reverse Split on the Ballot
Shareholders vote December 21, 2026 on a 5-to-1 reverse split that would recapitalize each five ordinary shares into one, reducing the 3,499,144 shares outstanding to roughly 700,000.
-
Authorized Shares Doubled to 24,000,000
Proposal 2 adds 12,000,000 authorized ordinary shares, taking the total to 24,000,000 — permission for future issuance, not shares sold. Post-split, registered capital would be 4,800,000 shares.
-
Nasdaq Delisting Still Pending
The split responds to Nasdaq's November 9 delisting determination after 30 consecutive days below $1.00; a Hearings Panel request stays suspension, and the Panel may grant up to 180 days, to May 8, 2027.
-
Interim CEO Pay and Options
Proposals 4 and 5 cover Efi Cohen-Arazi's US$132,000 annual fee (US$11,000 monthly, plus VAT) retroactive to March 26, 2026, and 100,000 options (20,000 post-split) vesting quarterly over two years.
Analysis · PRFX · Life Sciences
PRF is asking shareholders to approve a 5-to-1 reverse split at the December 21 AGM — the direct response to Nasdaq's November 9 delisting determination, which came after the stock traded below $1.00 for 30 straight days and the company was ineligible for the usual cure period because it already did a 1-for-5 split in February 2026. Approval would cut the 3,499,144 shares outstanding to roughly 700,000 and lift the per-share price toward the $1.00 threshold, but the filing itself warns the market price may not hold at the arithmetic result. The same ballot raises authorized capital from 12,000,000 to 24,000,000 shares, which is permission for future issuance, not dilution that has occurred — though it keeps the door open for more SEPA draws under the $15.0 million YA facility. Shareholders also vote on Interim CEO Efi Cohen-Arazi's US$132,000 annual fee and 100,000 options. A hearing before a Nasdaq Hearings Panel is pending and stays delisting; the Panel can grant up to 180 days, to May 8, 2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.64 to $7.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.